Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
A commercial claims analysis looking at 12-month divergent cost trends for 3 advanced cancers comparing 2013 & 2022 finds costs for newly diagnosed myeloma increased by 51% (from $216,337 to $327,495) due to immunotherapy.”
Title: Divergent Cost Trends for 3 Advanced Cancers, 2013 vs 2022: A Commercial Claims Analysis
Authors: M. Christopher Roebuck, Paul Fronstin, Troyen A. Brennan
You can read the full article on The American Journal of Managed Care.
You can find other articles featuring Robert Orlowski on OncoDaily.
